Can a simple blood test spot ovarian cancer before it starts?

NCT ID NCT07764744

First seen Aug 14, 2026 ยท Last updated Aug 14, 2026

Summary

This study is looking at whether a blood test called Galleri can help detect ovarian cancer early in people with BRCA1 or BRCA2 gene changes, who are at higher risk. Participants will give a blood sample and answer questionnaires about their experience. The study will also check how well the test finds ovarian cancer or precancerous conditions compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Galleri multi-cancer early detection (MCED) blood test
What this could lead to
If successful, this could lead to a simple blood test that helps catch ovarian cancer earlier in high-risk individuals, potentially improving outcomes.
What could go wrong
This is an early feasibility study with a small number of participants. The test may not be accurate enough for routine use, and results may not apply to the broader population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA 1 GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Weill Cornell Medicine

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.